Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients

European Neurology

Volumn 62, Issue 4, 2009, Pages 243-249

  Brioschi, Andrea ^a   Gramigna, Sandrine ^a   Werth, Esther ^b   Staub, Fabienne ^a   Ruffieux, Christiane ^a   Bassetti, Claudio ^b   Schluep, Myriam ^a   Annoni, Jean Marie ^a,b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Fatigue; Modafinil; Multiple sclerosis; Stroke

Indexed keywords

ANTIDEPRESSANT AGENT; BETA1A INTERFERON; INTERFERON BETA SERINE; MODAFINIL;

ADULT; AGGRESSIVENESS; ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIENCEPHALON; DISEASE SEVERITY; DIZZINESS; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXCITABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MOOD; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; OPEN STUDY; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SIDE EFFECT; SOMNOLENCE; STROKE; THORAX PAIN;

ADULT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP; STROKE; TREATMENT OUTCOME; WAKEFULNESS;

EID: 68349085674     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232927     Document Type: Article

References (36)

1. Chaudhuri A, Behan PO: Fatigue in neurological disorders. Lancet 2004; 20: 978-988.
2. Van de Werf SP, Jongen PJ, Lycklama A, Ni-jeholt GJ, Barkhof F, Hommes OR, Bleijen-berg G: Fatigue in multiple sclerosis: interrelations between complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci 1998; 160: 164-170.
3. Glader EL, Stegmayr B, Asplund K: Post-stroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002; 33: 1327-1333.
4. Bruno RL, Creange SJ, Frick NM: Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology? Am J Med 1998; 105: 66S-73S.
5. Staub F: Fatigue; in Bogousslavsky J, Gode-froy O (eds): Behavioural and Cognitive Neurology of Stroke. Cambridge, Cambridge University Press, 2007, pp 577-592.
6. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler J, Huber S, Ammann W, Plohmann A, Dellas S, Maguire R, Missimer J, Radü EW, Steck A, Leenders KL: Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-1571.
7. Bruno RL, Cohen JM, Galski T, Frick NM: The neuroanatomy of post-polio fatigue. Arch Phys Med Rehabil 1994; 75: 498-504.
8. Naess H, Nyland HI, Thomassen L, Aarseth J, Myhr KM: Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005; 20: 245-250.
9. Blondel-Hill, E, Safran SD: Treatment of the chronic fatigue syndrome. A review and practical guide. Drugs 1993; 46: 639-651.
10. Colombo B, Martinelli Boneschi F, Rossi P, et al: MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol 2000; 247: 506-509.
11. Saper CB, Scammell TE: Modafinil: a drug in search of a mechanism. Sleep 2004; 27: 11-12.
12. Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T: The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006; 22: 761-774.
13. Hou RH, Freeman C, Langley RW, Szabadi E, Bradshaw CM: Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers. Psychopharmacology 2005; 181: 535-549.
14. Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M; French Modafinil Study Group: Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64: 1139-1143.
15. Ballon JS, Feifel D: A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554-566.
16. Schwartz JRL: Modafinil: new indications for wake promotion. Expert Opin Pharmacother 2005; 6: 115-129.
17. Van Zandvoort MJE, Kappelle LJ, Algra A, De Haan EHF: Decreased capacity for mental effort after single supratentorial lacunar infarct may affect performance in everyday life. J Neurol Neurosurg Psychiatry 1998; 65: 697-702.
18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text revision (DSM-IV-TR). Washington, American Psychiatric Association, 2000.
19. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
20. Kurtzke J: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
21. Schwartz JE, Jandorf L, Krupp LB: The measurement of fatigue: a new instrument. J Psychosom Res 1993; 37: 753-762.
22. Rankin J: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957; 2: 200-215.
23. Mahoney FI, Barthel D: Functional evaluation: the Barthel index. Md State Med J 1965; 14: 56-61.
24. Bassetti CL, Valko P: Poststroke hypersomnia. Sleep Med Clin 2006; 1: 139-155.
25. Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
26. Zimmermann P, Fimm B: Test for Attentional Performance. Freiburg, Psytest, 1994.
27. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scan 1983; 67: 361-370.
28. Kraft GH, Bowen J, Stankoff B, Waubant E, Lubetzki C, Clanet M: Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 65: 1995-1997.
29. Sadeh A, Hauri PJ, Kripke DF, Lavie P: The role of actigraphy in the evaluation of sleep disorders. Sleep 1995; 18: 288-302.
30. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja AN: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179-183.
31. Zifko UA, Rupp M, Schwartz S, Zipko HT, Maida EM: Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002; 249: 983-987.
32. Bassetti CL: Sleep and stroke. Semin Neurol 2005; 25: 19-32.
33. Tafti M, Nishino S, Liao W, Dement WC, Mignot E: Mesopontine organization of cho-linergic and catecholaminergic cell groups in the normal and narcoleptic dog. J Comp Neurol 1997; 379: 185-197.
34. Overeem S, Mignot E, Gert van Dijk J, Lam-mers G: Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001; 18: 78-105.
35. Gill M, Haerich P, Westcott K, Godenik KL, Tucker JA: Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 2006; 13: 158-165.
36. Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ: Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006; 11: 93-102.